ID
15433
Descripción
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Repitition of Assessments Please complete the following pages only if Baseline Assessments had to be repeated prior to initiation of Lemtrada® (relapse after first examination, see Study Protocol 8.1.1.2)
Link
https://clinicaltrials.gov/ct2/show/NCT02419378
Palabras clave
Versiones (1)
- 31/5/16 31/5/16 -
Subido en
31 de mayo de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Baseline: Repitition of Assessments: EDSS Multiple Sclerosis ALAIN01 NCT02419378
Baseline: Repitition of Assessments EDSS Multiple Sclerosis ALAIN01 NCT02419378
Similar models
Baseline: Repitition of Assessments EDSS Multiple Sclerosis ALAIN01 NCT02419378
C0011008 (UMLS CUI [1,2])
C1321512 (UMLS CUI [1,2])
C0006121 (UMLS CUI [1,2])
C0228060 (UMLS CUI [1,2])
C0007765 (UMLS CUI [1,2])
C0682648 (UMLS CUI [1,2])
C0006104 (UMLS CUI [1,2])
C0080331 (UMLS CUI [1,2])
C0007765 (UMLS CUI [1,2])
Sin comentarios